A Phase 3 interventional study of Olaparib 300mg tablets and Placebo to match olaparib 300mg in Platinum Sensitive, BRCA Mutated and Relapsed Ovarian Cancer, sponsored by AstraZeneca. Active, not recruiting at 126 sites in 17 countries. Open to female participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2026-07-29.
Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 69 studies testing olaparib in Ovarian Neoplasms — 13 open to participants now, 26 under way, 9 of them phase 3. olaparib · Ovarian Neoplasms.
Among the 69 studies testing olaparib in Ovarian Neoplasms, this one is the 11th largest by enrollment, is one of 2 that started in 2013, is one of 16 in phase 3, reaches primary completion later than 1 of the 25 other live ones, and was the 14th registered.
3,387 studies on the registry are indexed under Ovarian Neoplasms; 792 are open to participants now.
Browse Ovarian Neoplasms studies →13 of the 69 studies testing olaparib in Ovarian Neoplasms are open now, in 8 countries. Recruiting first, the newest first:
Bai-Rong Xia · Sites in China
Ages 18–75 · Women only
Daewoong Pharmaceutical Co. LTD. · Sites in Korea, Republic of
Ages 19+ · Women only
Boryung Pharmaceutical Co., Ltd · Sites in Korea, Republic of
Ages 19–74 · Women only
The Netherlands Cancer Institute · Sites in Netherlands
Ages 18–100 · Women only
NRG Oncology · Sites in United States, Japan, Puerto Rico
Ages 18+
By country, each count listing its studies:
olaparib: first FDA approval 2014 (LYNPARZA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 605 Ovarian Neoplasms studies recruiting now, 442 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.
This study: 18 Years to 130 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, olaparib is the treatment under test here. Read study by study →
69 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 17 · Phase 2 35 · Phase 3 17 · Phase 4 3
First in 2005; this study’s year is marked. 2 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 327 is above the median of 54 across 2,552 interventional studies indexed under Ovarian Neoplasms.
Median enrollment 97 across the 69 interventional studies. Of the 32 that completed or were terminated, 16 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
27 of 69 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
70 studies in Ovarian Neoplasms by AstraZeneca: 8 open now, 20 under way, 6 of them phase 3. Of 45 finished, 15 (33%) have results posted.
Among the 70 studies in Ovarian Neoplasms by AstraZeneca, this one is the 11th largest by enrollment of the 47 interventional ones that give a count, is one of 2 that started in 2013, is one of 11 in phase 3, reaches primary completion later than 1 of the 19 other live ones, and was the 14th registered.
AstraZeneca’s Ovarian Neoplasms studies by the year they started, since 2001.
5 of the studies testing olaparib in Ovarian Neoplasms that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04421963Phase 3AstraZenecaRoll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib | 2027-04-06 |
| NCT03579316M.D. Anderson Cancer CenterAdavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | 2026-12-31 |
| NCT07371104Daewoong Pharmaceutical Co. LTD.Bioequivalence Study of DWZ2501 in Patients With Advanced BRCA-mutated High-grade Ovarian Cancer | 2027-03 |
| NCT07460180The Netherlands Cancer InstituteThe PROOV Study: Exploiting the Synergistic Effect of PARP Inhibition With Cisplatin and Hyperthermia During Interval Cytoreductive Surgery and HIPEC in Ovarian Cancer | 2027-05-01 |
| NCT03943173M.D. Anderson Cancer CenterOlaparib in Treating Patients With Newly Diagnosed BRCA-Mutant Ovarian, Primary Peritoneal, or Fallopian Cancer Before Surgery | 2027-06-27 |
Add all 5 to your calendar (.ics) → With an account.
Among the 69 studies testing olaparib in Ovarian Neoplasms, from their registry updates:
Among AstraZeneca’s 70 in Ovarian Neoplasms:
This tab as a report to print or save as PDF → With an account.
A Phase III, randomised, double-blind, placebo-controlled, multi-centre study to assess the efficacy of olaparib maintenance monotherapy in relapsed high grade serous ovarian cancer (HGSOC) patients (including patients with primary peritoneal and / or fallopian tube cancer) or high grade endometrioid cancer with BRCA mutations (documented mutation in BRCA1 or BRCA2 that is predicted to be deleterious or suspected deleterious (known or predicted to be detrimental/lead to loss of function)) who have responded following platinum based chemotherapy.
Comparison of olaparib against a placebo in patients with ovarian cancer whose cancer has already improved by taking platinum based chemotherapy. The patients must also have a fault in their DNA which codes for the BRCA protein. The BRCA protein helps mend broken DNA in the cells of the body; if this protein doesn't work properly it can increase the chance of getting cancer. The aim of this study is to see whether patients taking olaparib tablets last longer until their cancer gets worse, compared to those taking the placebo tablet. The study is also looking to see if there is an overall improvement to how long the patients survive whilst taking olaparib tablets compared to the placebo tablets; and the quality of their life whilst living with ovarian cancer.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients must be ≥ 18 years of age.
For the penultimate chemotherapy course prior to enrolment on the study:
For the last chemotherapy course immediately prior to randomisation on the study:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Taken orally twice daily
Drug: Olaparib 300mg tablets
Taken orally twice daily
Drug: Placebo to match olaparib 300mg
300mg Olaparib or placebo tablets taken orally twice daily until objective radiological disease progression as per RECIST as assessed by the investigator (or as long as in the investigator's opinion they are benefiting from treatment and they do not meet any other discontinuation criteria). Dose reduction to 250mg and subsequently 200mg is permitted following confirmation of toxicity.
300mg Olaparib or placebo tablets taken orally twice daily until objective radiological disease progression as per RECIST as assessed by the investigator (or as long as in the investigator's opinion they are benefiting from treatment and they do not meet any other discontinuation criteria). Dose reduction to 250mg and subsequently 200mg is permitted following confirmation of toxicity.
Progression Free Survival (PFS) Using Investigator Assessment According to Modified Response Evaluation Criteria In Solid Tumours (RECIST 1.1)
To determine the efficacy by progression free survival (PFS) (using investigator assessment according to modified Response Evaluation Criteria In Solid Tumours (RECIST 1.1)) of olaparib maintenance monotherapy compared to placebo in BRCA mutated relapsed ovarian cancer patients who are in complete or partial response following platinum based chemotherapy.
Time frame: Radiologic scans performed at baseline then every ~12 weeks up to 72 weeks, then every ~ 24 weeks thereafter until objective radiological disease progression. Assessed until 19 Sep 2016 DCO (16 Jan 2017 DCO for China Cohort); up to a maximum of 36 months.
Efficacy in Patients Following Platinum Based Chemotherapy by Assessment of Overall Survival
To determine the efficacy of olaparib maintenance monotherapy compared to placebo in BRCA mutated relapsed ovarian cancer patients who are in complete or partial response following platinum based chemotherapy by assessment of overall survival (OS).
Time frame: Survival assessed every 4 weeks until treatment discontinues, then every 12 weeks. Assessed until 03 Feb 2020 DCO; up to a maximum of 75 months.
Efficacy in Patients Following Platinum Based Chemotherapy by Assessment of Time to Earliest Progression by RECIST or Cancer Antigen (CA-125) or Death
To determine the efficacy of olaparib maintenance monotherapy compared to placebo in BRCA mutated relapsed ovarian cancer patients who are in complete or partial response following platinum based chemotherapy by assessment of time to earliest progression by RECIST or CA-125 or death.
Time frame: CA-125 at baseline then every 4 wks. Radiologic scans at baseline then every ~12 wks up to 72 wks, then every ~ 24 wks until objective radiological disease progression. Assessed until 19Sep2016 DCO (16Jan2017 DCO for China Cohort); up to a max of 36 mths.
Efficacy in Patients Following Platinum Based Chemotherapy by Assessment of Time From Randomization to Second Progression
To determine the efficacy of olaparib maintenance monotherapy compared to placebo in BRCA mutated relapsed ovarian cancer patients who are in complete response or partial response following first line platinum based chemotherapy by assessment of time from randomization up to second progression
Time frame: Scans at baseline then every 12 wks for 72 wks, then every 24 wks until first progression. Assessments then per local practice every 12 wks until second progression. Assessed until 19Sep2016 DCO (16Jan2017 DCO for China Cohort); up to a max of 36 mths
Change From Baseline in Health-Related Quality of Life (HRQoL) as Assessed by the the Trial Outcome Index (TOI) of the Functional Assessment of Cancer Therapy - Ovarian (FACT-O)
To compare the effects of olaparib maintenance monotherapy compared to placebo on Health-related Quality of Life (HRQoL) as assessed by the trial outcome index (TOI) of the Functional Assessment of Cancer Therapy - Ovarian (FACT-O) in BRCA mutated relapsed ovarian cancer patients who are in complete or partial response following platinum based chemotherapy. The TOI ranges from 0-100 and a higher score indicates a higher HRQoL.
Time frame: Questionnaires completed by patient at baseline, Day 29 and then every 12 weeks for 12 months. Assessed until 19 Sep 2016 DCO.
Efficacy of Olaparib by Time to First Subsequent Therapy or Death (TFST)
To determine the efficacy of olaparib maintenance monotherapy compared to placebo in BRCA mutated high risk advanced ovarian cancer patients who are in clinical complete response or partial response following first line platinum based chemotherapy by assessment of time from randomization to first subsequent therapy or death (TFST).
Time frame: Time elapsed from randomization to first subsequent therapy or death. Assessed every 12 weeks following treatment discontinuation. Assessed until 03 Feb 2020 DCO; up to a maximum of 75 months.
Efficacy of Olaparib by Time to Second Subsequent Therapy or Death (TSST)
To determine the efficacy of olaparib maintenance monotherapy compared to placebo in BRCA mutated high risk advanced ovarian cancer patients who are in clinical complete response or partial response following first line platinum based chemotherapy by assessment of time from randomization to second subsequent therapy or death (TSST).
Time frame: Time elapsed from randomization to second subsequent therapy or death. Assessed every 12 weeks following treatment discontinuation. Assessed until 03 Feb 2020 DCO; up to a maximum of 75 months.
Efficacy of Olaparib by Time From Randomization to Study Treatment Discontinuation or Death (TDT)
To determine the efficacy of olaparib maintenance monotherapy compared to placebo in BRCA mutated high risk advanced ovarian cancer patients who are in clinical complete response or partial response following first line platinum based chemotherapy by assessment of time from randomization to study treatment discontinuation or death (TDT).
Time frame: Time elapsed from randomization to study treatment discontinuation or death. Assessed until 03 Feb 2020 DCO; up to a maximum of 75 months.
Efficacy in Patients With a Deleterious or Suspected Deleterious Variant in Either of the BRCA Genes by Assessment of PFS.
To assess efficacy of olaparib in patients identified as having a deleterious or suspected deleterious variant in either of the BRCA genes using variants identified with current and future BRCA mutation assays (gene sequencing and large rearrangement analysis).
Time frame: Radiologic scans performed at baseline then every ~12 weeks for the first 72 weeks, then every ~24 weeks thereafter, assessed until disease progression. Assessed until 19 Sep 2016 DCO.
To Determine the Exposure to Olaparib by Pharmacokinetic Analysis
To determine the exposure to olaparib in patients receiving olaparib maintenance monotherapy
Time frame: Pharmacokinetics sampling to be performed in a subset of patients. Sampling times: Day 1 pre-dose & 1 hour; Day 15 pre-dose & 1 hour; Day 29 pre-dose. Assessed until 19 Sep 2016 DCO.
Global Cohort: First patient screened: 03 Sep 2013; last patient screened on 21 Nov 2014. 602 patients screened across 119 centres in 16 countries; 295 were randomized. Results are reported for analysis of PFS (DCO: 19 Sep 2016) and OS (DCO: 03 Feb 2020). China Cohort: First patient enrolled: 07 Apr 2015; last patient enrolled: 30 Oct 2015. 127 patients screened across 16 sites; 32 were randomized. Results are reported for analysis of PFS (DCO: 16 Jan 2017) and OS (DCO: 03 Feb 2020).
| Milestone | Olaparib 300mg Tablets (Global Cohort) | Placebo Tablets (Global Cohort) | Olaparib 300mg Tablets (China Cohort) | Placebo Tablets (China Cohort) |
|---|---|---|---|---|
| Started | 196 | 99 | 22 | 10 |
| Completed | 69 | 26 | 7 | 3 |
| Not completed | 127 | 73 | 15 | 7 |
| Withdrew: One patient was unblinded and one patient was randomised in error | 2 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 2 | 2 | 2 | 0 |
| Withdrew: Death | 110 | 60 | 13 | 7 |
| Withdrew: Withdrawal by subject | 13 | 11 | 0 | 0 |
To determine the efficacy by progression free survival (PFS) (using investigator assessment according to modified Response Evaluation Criteria In Solid Tumours (RECIST 1.1)) of olaparib maintenance monotherapy compared to placebo in BRCA mutated relapsed ovarian cancer patients who are in complete or partial response following platinum based chemotherapy.
| Months | Olaparib 300mg Tablets (Global Cohort) | Placebo Tablets (Global Cohort) | Olaparib 300mg Tablets (China Cohort) | Placebo Tablets (China Cohort) |
|---|---|---|---|---|
| Progression Free Survival (PFS) Using Investigator Assessment According to Modified Response Evaluation Criteria In Solid Tumours (RECIST 1.1) | 19.1 (16.3 to 25.7) | 5.5 (5.2 to 5.8) | 13.8 (6.5 to 16.6) | 5.5 (2.7 to NA) |
To determine the efficacy of olaparib maintenance monotherapy compared to placebo in BRCA mutated relapsed ovarian cancer patients who are in complete or partial response following platinum based chemotherapy by assessment of overall survival (OS).
| Months | Olaparib 300mg Tablets (Global Cohort) | Placebo Tablets (Global Cohort) | Olaparib 300mg Tablets (China Cohort) | Placebo Tablets (China Cohort) |
|---|---|---|---|---|
| Efficacy in Patients Following Platinum Based Chemotherapy by Assessment of Overall Survival | 51.7 (41.5 to 59.1) | 38.8 (31.4 to 48.6) | 41.7 (17.6 to NA) | 36.4 (13.2 to NA) |
To determine the efficacy of olaparib maintenance monotherapy compared to placebo in BRCA mutated relapsed ovarian cancer patients who are in complete or partial response following platinum based chemotherapy by assessment of time to earliest progression by RECIST or CA-125 or death.
| Months | Olaparib 300mg Tablets (Global Cohort) | Placebo Tablets (Global Cohort) | Olaparib 300mg Tablets (China Cohort) | Placebo Tablets (China Cohort) |
|---|---|---|---|---|
| Efficacy in Patients Following Platinum Based Chemotherapy by Assessment of Time to Earliest Progression by RECIST or Cancer Antigen (CA-125) or Death | 16.9 (14.6 to 22.3) | 4.9 (3.7 to 5.6) | 12.9 (5.9 to 14.0) | 3.7 (1.0 to 7.4) |
To determine the efficacy of olaparib maintenance monotherapy compared to placebo in BRCA mutated relapsed ovarian cancer patients who are in complete response or partial response following first line platinum based chemotherapy by assessment of time from randomization up to second progression
| Months | Olaparib 300mg Tablets (Global Cohort) | Placebo Tablets (Global Cohort) | Olaparib 300mg Tablets (China Cohort) | Placebo Tablets (China Cohort) |
|---|---|---|---|---|
| Efficacy in Patients Following Platinum Based Chemotherapy by Assessment of Time From Randomization to Second Progression | NA (24.1 to NA) | 18.4 (15.4 to 22.8) | NA (NA to NA) | 17.3 (6.0 to 17.3) |
To compare the effects of olaparib maintenance monotherapy compared to placebo on Health-related Quality of Life (HRQoL) as assessed by the trial outcome index (TOI) of the Functional Assessment of Cancer Therapy - Ovarian (FACT-O) in BRCA mutated relapsed ovarian cancer patients who are in complete or partial response following platinum based chemotherapy. The TOI ranges from 0-100 and a higher score indicates a higher HRQoL.
| Change in TOI over 12 months | Olaparib 300mg Tablets (Global Cohort) | Placebo Tablets (Global Cohort) |
|---|---|---|
| Change From Baseline in Health-Related Quality of Life (HRQoL) as Assessed by the the Trial Outcome Index (TOI) of the Functional Assessment of Cancer Therapy - Ovarian (FACT-O) | -2.90 (-4.131 to -1.673) | -2.87 (-4.643 to -1.097) |
To determine the efficacy of olaparib maintenance monotherapy compared to placebo in BRCA mutated high risk advanced ovarian cancer patients who are in clinical complete response or partial response following first line platinum based chemotherapy by assessment of time from randomization to first subsequent therapy or death (TFST).
| Months | Olaparib 300mg Tablets (Global Cohort) | Placebo Tablets (Global Cohort) | Olaparib 300mg Tablets (China Cohort) | Placebo Tablets (China Cohort) |
|---|---|---|---|---|
| Efficacy of Olaparib by Time to First Subsequent Therapy or Death (TFST) | 27.4 (22.6 to 31.1) | 7.2 (6.3 to 8.5) | 13.9 (9.1 to 15.9) | 5.5 (1.4 to 18.4) |
To determine the efficacy of olaparib maintenance monotherapy compared to placebo in BRCA mutated high risk advanced ovarian cancer patients who are in clinical complete response or partial response following first line platinum based chemotherapy by assessment of time from randomization to second subsequent therapy or death (TSST).
| Months | Olaparib 300mg Tablets (Global Cohort) | Placebo Tablets (Global Cohort) | Olaparib 300mg Tablets (ChinaCohort) | Placebo Tablets (China Cohort) |
|---|---|---|---|---|
| Efficacy of Olaparib by Time to Second Subsequent Therapy or Death (TSST) | 35.8 (29.4 to 43.9) | 18.9 (15.5 to 21.5) | 19.0 (10.1 to 32.8) | 26.4 (6.3 to 36.0) |
To determine the efficacy of olaparib maintenance monotherapy compared to placebo in BRCA mutated high risk advanced ovarian cancer patients who are in clinical complete response or partial response following first line platinum based chemotherapy by assessment of time from randomization to study treatment discontinuation or death (TDT).
| Months | Olaparib 300mg Tablets (Global Cohort) | Placebo Tablets (Global Cohort) | Olaparib 300mg Tablets (China Cohort) | Placebo Tablets (China Cohort) |
|---|---|---|---|---|
| Efficacy of Olaparib by Time From Randomization to Study Treatment Discontinuation or Death (TDT) | 19.4 (14.9 to 25.9) | 5.6 (5.0 to 6.8) | 13.4 (6.3 to 16.5) | 4.7 (1.3 to 11.1) |
To assess efficacy of olaparib in patients identified as having a deleterious or suspected deleterious variant in either of the BRCA genes using variants identified with current and future BRCA mutation assays (gene sequencing and large rearrangement analysis).
| Months | Olaparib 300mg Tablets (Global Cohort) | Placebo Tablets (Global Cohort) |
|---|---|---|
| Efficacy in Patients With a Deleterious or Suspected Deleterious Variant in Either of the BRCA Genes by Assessment of PFS. | 19.3 (16.5 to 27.3) | 5.5 (5.0 to 5.8) |
To determine the exposure to olaparib in patients receiving olaparib maintenance monotherapy
| mcg/mL | Olaparib 300mg Tablets |
|---|---|
| Day 1 - Pre-dose | NA ± NA |
| Day 1 - 1 hour | 3.26 ± 312.2 |
| Day 15 - Pre-dose | 0.92 ± 95.5 |
| Day 15 - 1 hour | 5.12 ± 61.8 |
| Day 29 - Pre-dose | 0.94 ± 179.0 |
Collected over Includes adverse events with an onset date on or after the date of first dose and up to and including 30 days following the date of last dose of olaparib/placebo.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Olaparib 300 Tablets (Global Cohort) | 116/196 (59.2%) | 50/195 (25.6%) | 192/195 (98.5%) |
| Placebo Tablets (Global Cohort) | 65/99 (65.7%) | 8/99 (8.1%) | 91/99 (91.9%) |
| Olaparib 300 Tablets (China Cohort) | 13/22 (59.1%) | 5/22 (22.7%) | 21/22 (95.5%) |
| Placebo Tablets (China Cohort) | 7/10 (70%) | 1/10 (10%) | 10/10 (100%) |
| Event | Olaparib 300 Tablets (Global Cohort) | Placebo Tablets (Global Cohort) | Olaparib 300 Tablets (China Cohort) | Placebo Tablets (China Cohort) |
|---|---|---|---|---|
| GastroenteritisInfections and infestations | 0/195 | 0/99 | 0/22 | 1/10 |
| AnaemiaBlood and lymphatic system disorders | 8/195 | 0/99 | 2/22 | 0/10 |
| NeutropeniaBlood and lymphatic system disorders | 1/195 | 0/99 | 1/22 | 0/10 |
| Food poisoningGastrointestinal disorders | 0/195 | 0/99 | 1/22 | 0/10 |
| White blood cell count decreasedInvestigations | 0/195 | 0/99 | 1/22 | 0/10 |
| LeukopeniaBlood and lymphatic system disorders | 0/195 | 0/99 | 1/22 | 0/10 |
| Haemoglobin decreasedInvestigations | 0/195 | 0/99 | 1/22 | 0/10 |
| Neutrophil count decreasedInvestigations | 0/195 | 0/99 | 1/22 | 0/10 |
| Abdominal painGastrointestinal disorders | 4/195 | 0/99 | 0/22 | 0/10 |
| Intestinal obstructionGastrointestinal disorders | 4/195 | 1/99 | 0/22 | 0/10 |
| Event | Olaparib 300 Tablets (Global Cohort) | Placebo Tablets (Global Cohort) | Olaparib 300 Tablets (China Cohort) | Placebo Tablets (China Cohort) |
|---|---|---|---|---|
| NauseaGastrointestinal disorders | 148/195 | 35/99 | 18/22 | 1/10 |
| AnaemiaBlood and lymphatic system disorders | 83/195 | 9/99 | 7/22 | 0/10 |
| VomitingGastrointestinal disorders | 77/195 | 20/99 | 8/22 | 1/10 |
| FatigueGeneral disorders | 75/195 | 15/99 | 7/22 | 2/10 |
| Decreased appetiteMetabolism and nutrition disorders | 44/195 | 11/99 | 8/22 | 2/10 |
| DiarrhoeaGastrointestinal disorders | 67/195 | 20/99 | 4/22 | 0/10 |
| Upper respiratory tract infectionInfections and infestations | 17/195 | 6/99 | 7/22 | 2/10 |
| AstheniaGeneral disorders | 62/195 | 27/99 | 2/22 | 0/10 |
| Abdominal painGastrointestinal disorders | 53/195 | 31/99 | 3/22 | 0/10 |
| Abdominal distensionGastrointestinal disorders | 13/195 | 7/99 | 3/22 | 3/10 |
Global Cohort: 196 Olaparib, 99 Placebo China Cohort: 22 Olaparib, 10 Placebo
| Age, Continuous(Years) | Olaparib 300mg Tablets | Placebo Tablets | Total |
|---|---|---|---|
| Global Cohort | 57.0 ± 9.2 | 56.6 ± 8.9 | 56.9 ± 9.09 |
| China Cohort | 50.6 ± 8.42 | 47.4 ± 9.29 | 49.6 ± 8.68 |
| Age, Customized(Participants) | Olaparib 300mg Tablets | Placebo Tablets | Total |
|---|---|---|---|
| Global Cohort — <50 | 38 | 25 | 63 |
| Global Cohort — >=50-<65 | 118 | 52 | 170 |
| Global Cohort — >=65 | 40 | 22 | 62 |
| China Cohort — <50 | 11 | 7 | 18 |
| China Cohort — >=50-<65 | 10 | 2 | 12 |
| China Cohort — >=65 | 1 | 1 | 2 |
| Sex: Female, Male(Participants) | Olaparib 300mg Tablets | Placebo Tablets | Total |
|---|---|---|---|
| Global Cohort — Female | 196 | 99 | 295 |
| Global Cohort — Male | 0 | 0 | 0 |
| China Cohort — Female | 22 | 10 | 32 |
| China Cohort — Male | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | Olaparib 300mg Tablets | Placebo Tablets | Total |
|---|---|---|---|
| Global Cohort — Hispanic or Latino | 10 | 1 | 11 |
| Global Cohort — Not Hispanic or Latino | 186 | 98 | 284 |
| Global Cohort — Unknown or Not Reported | 0 | 0 | 0 |
| China Cohort — Hispanic or Latino | 0 | 0 | 0 |
| China Cohort — Not Hispanic or Latino | 22 | 10 | 32 |
| China Cohort — Unknown or Not Reported | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Olaparib 300mg Tablets | Placebo Tablets | Total |
|---|---|---|---|
| Global Cohort — WHITE | 173 | 91 | 264 |
| Global Cohort — BLACK OR AFRICAN AMERICAN | 1 | 0 | 1 |
| Global Cohort — AMERICAN INDIAN OR ALASKA NATIVE | 0 | 0 | 0 |
| Global Cohort — ASIAN | 22 | 7 | 29 |
| Global Cohort — NATIVE HAWAIIAN OR OTHER PACIFIC ISLANDER | 0 | 0 | 0 |
| Global Cohort — OTHER | 0 | 1 | 1 |
| China Cohort — WHITE | 0 | 0 | 0 |
| China Cohort — BLACK OR AFRICAN AMERICAN | 0 | 0 | 0 |
| China Cohort — AMERICAN INDIAN OR ALASKA NATIVE | 0 | 0 | 0 |
| China Cohort — ASIAN | 22 | 10 | 32 |
| China Cohort — NATIVE HAWAIIAN OR OTHER PACIFIC ISLANDER | 0 | 0 | 0 |
| China Cohort — OTHER | 0 | 0 | 0 |
Showing the first 100 of 126 sites across 17 countries. Choose a country and city above to see the rest.
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Supporting information: Study protocol, Statistical analysis plan
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com
Ran from Sep 2013 to primary completion in Sep 2016, 36 months.
Results were first posted in Feb 2018, 1 year 4 months after primary completion.
Of 73 industry-sponsored phase 3 interventional studies under Ovarian Neoplasms, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 72. This study's 36 months is below that.
Counting every sponsor, half of 125 studies reached it within 59 months; a quarter within 37 and three quarters within 89.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Olaparib